北陆药业(300016) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥255,786,983.47, representing a year-on-year increase of 20.77%[2] - The net profit attributable to shareholders for the same period was ¥4,853,098.55, a significant increase of 163.36% compared to the previous year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,104,651.19, up 145.62% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0099, an increase of 163.46% year-on-year[3] - The diluted earnings per share for the same period was ¥0.0292, showing a remarkable increase of 906.90% compared to the previous year[3] - Total operating revenue for Q3 2024 reached ¥729,717,058.01, an increase of 12.3% compared to ¥649,819,616.22 in the same period last year[21] - Net profit for Q3 2024 was ¥19,003,632.36, a significant recovery from a net loss of ¥4,214,435.41 in the previous year[22] - Earnings per share (EPS) for Q3 2024 were reported at ¥0.0497, compared to ¥0.0040 in the same quarter last year, indicating a substantial improvement[22] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥137,565,034.78, reflecting a 124.68% increase compared to the same period last year[7] - Operating cash inflow for the period reached ¥864,976,237.96, an increase of 26.4% compared to ¥684,165,993.62 in the previous period[23] - Net cash flow from operating activities was ¥137,565,034.78, significantly up from ¥61,225,996.09 in the prior period, marking a 125.0% increase[23] - Cash inflow from financing activities was ¥148,374,600.00, down from ¥295,519,043.58 in the previous period, reflecting a decrease of 49.9%[24] - Net cash flow from financing activities was ¥635,488.11, a decline from ¥46,618,494.57 in the prior period[24] - The ending balance of cash and cash equivalents was ¥244,766,266.16, a significant decrease from ¥736,672,781.82 in the previous period[24] - The company received ¥20,339,652.89 in other operating cash related to business activities, up from ¥15,246,185.69 in the previous period, representing a 33.6% increase[23] - The company reported a cash inflow of ¥832,994,246.29 from other investment activities, a substantial increase from ¥430,300,000.00 in the previous period[24] - The company’s cash flow from sales of goods and services was ¥839,138,771.77, compared to ¥663,150,517.07 in the previous period, reflecting a growth of 26.6%[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,010,674,509.18, a 6.78% increase from the end of the previous year[3] - The total assets increased to 3,010,674,509.18 yuan, up from 2,819,424,047.96 yuan in the previous period, reflecting a growth in the company's asset base[17] - The company’s non-current assets totaled 1,797,059,111.75 yuan, an increase from 1,622,631,959.82 yuan, indicating growth in long-term investments[17] - The total liabilities increased to ¥1,162,669,414.13 from ¥1,033,111,812.55, representing a growth of 12.5% year-over-year[21] - The company’s total liabilities increased, with accounts payable rising to 100,258,362.68 yuan from 95,057,517.19 yuan, reflecting higher operational costs[17] - The company's short-term borrowings increased to 190,304,423.34 yuan from 175,563,188.54 yuan, indicating a rise in debt levels[17] Research and Development - The company has made progress in its R&D projects, although some projects have not yet reached milestone nodes, leading to a temporary reduction in R&D expenditures[7] - Research and development expenses for the quarter were ¥53,171,942.94, a decrease of 38.4% from ¥86,346,507.94 in the previous year[21] Product Development and Market Operations - The company is actively promoting products included in centralized procurement and has seen steady growth in overseas market operations, contributing to revenue growth[7] - The company received approvals for several products, including Gadobutrol injection and Paroxetine hydrochloride enteric-coated sustained-release tablets, enhancing its product portfolio[14] Inventory and Receivables - Inventory rose to 323,934,232.06 yuan, compared to 244,859,077.90 yuan previously, suggesting an increase in stock levels[16] - Accounts receivable decreased to 154,380,207.23 yuan from 185,043,282.81 yuan, showing improved collection efficiency[16] - The company reported a total of 1,213,615,397.43 yuan in current assets, slightly up from 1,196,792,088.14 yuan[16]